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Summary
MicroRNA (miRNA) expression profiles for lung cancers were examined to investigate miRNA’s involvement in lung carcino-
genesis. miRNA microarray analysis identified statistical unique profiles, which could discriminate lung cancers from non-
cancerous lung tissues as well as molecular signatures that differ in tumor histology. miRNA expression profiles correlated
with survival of lung adenocarcinomas, including those classified as disease stage I. High hsa-mir-155 and low hsa-let-7a-2
expression correlated with poor survival by univariate analysis as well as multivariate analysis for hsa-mir-155. The miRNA
expression signature on outcome was confirmed by real-time RT-PCR analysis of precursor miRNAs and crossvalidated
with an independent set of adenocarcinomas. These results indicate that miRNA expression profiles are diagnostic and
prognostic markers of lung cancer.Introduction
Lung cancer is the leading cause of cancer deaths in the world,
and its etiology is primarily genetic and epigenetic damage
caused by tobacco smoke (Travis et al., 2004). Systematic anal-
ysis ofmRNA and protein expression levels among thousands of
genes has also contributed to defining the molecular network of
lung carcinogenesis (Meyerson and Carbone, 2005; Granville
and Dennis, 2005). Defects in both the p53 and RB/p16 path-
ways are common in lung cancer. Several other genes, such
as K-ras, PTEN, FHIT, and MYO18B, are genetically altered,
though less frequently (Minna et al., 2002; Sekido et al., 2003;
Yokota and Kohno, 2004). Although focusing on known genes
and proteins has already yielded new information, previously un-
known markers such as noncoding RNA gene products may
also lend insight into the biology of lung cancer.CANCER CELL 9, 189–198, MARCH 2006 ª2006 ELSEVIER INC. DOI 10MicroRNAs (miRNAs) are small noncoding RNA gene prod-
ucts about 22 nt long that are found in diverse organisms and
play key roles in regulating the translation and degradation
of mRNAs through base pairing to partially complementary
sites, predominately in the untranslated region of the message
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros,
2001). miRNAs are expressed as long precursor RNAs that are
processed by a cellular nuclease, Drosha, before being trans-
ported by an Exportin-5-dependent mechanism into the cyto-
plasm (Yi et al., 2003;GregoryandShiekhattar, 2005).Once in the
cytoplasm, miRNAs are cleaved further by the enzyme DICER
(Lee et al., 2002, 2003), and this results in 17–24 nt miRNAs
that are associated with a cellular complex that is similar to the
RNA-induced silencing complex that participates in RNA inter-
ference (Hutvagner andZamore, 2002). Recently, it was reported
that DICER expression levels were reduced in a fraction of lungS I G N I F I C A N C E
miRNAs are a class of small noncoding RNA genes found to be abnormally expressed in several types of cancer, suggesting that
miRNAs play a substantial role in the pathogenesis of human cancers. Lung cancer is the leading cause of cancer deaths in the world,
reflecting the need for a better understanding of the mechanisms that underlie lung carcinogenesis. Although focusing on known
genes and proteins has already yielded new information, unknown markers may also lend insight into the biology of lung cancer.
We showed that lung cancer has extensive alterations of miRNA expression that may deregulate cancer-related genes. Furthermore,
themiRNAmolecular signature of lung adenocarcinomas, including those without evidence of metastasis, also correlates with patient
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A R T I C L Ecancers with a significant prognostic impact on patient survival
(Karube et al., 2005). The biological functions of most miRNAs
are not yet fully understood. It has been suggested that the
miRNAs are involved in various biological processes, including
cell proliferation, cell death, stress resistance, and fat metabo-
lism, through the regulation of gene expression (Ambros, 2003).
Our understanding of miRNA expression patterns and func-
tion in normal or neoplastic human cells is just starting to
emerge. miRNA genes are frequently located at fragile sites
(FRAs), as well as in minimal regions of loss of heterozygosity,
minimal regions of amplification, or common breakpoint re-
gions, suggesting that miRNAs might be a new class of genes
involved in human tumorigenesis (Calin et al., 2004b). For exam-
ple, mir-15-a andmir-16-1 are frequently deleted and/or down-
regulated in patients with B cell chronic lymphocytic leukemia
(Calin et al., 2002). Other links between cancer and miRNA
have been reported, including reduced expression of mir-143
and mir-145 in colorectal cancers (Michael et al., 2003) and
let-7 in lung cancers (Takamizawa et al., 2004), high expression
of the precursor mir-155 in Burkitt’s lymphomas (Metzler et al.,
2004), and oncogenic function of mir-17-92 cluster in human B
cell lymphomas as well as in lung cancers (He et al., 2005; Hay-
ashita et al., 2005). The precise mechanisms regulating miRNA
expression are unknown. However, several mechanisms, in-
cluding genetic and epigenetic alteration, might affect miRNA
expression, and theymay lead to alterations in the pattern of tar-
get genes expression in cancers. It was shown that miRNA ex-
pression patterns have relevance to the biological and clinical
behavior of human B cell chronic lymphocytic leukemia and
solid tumors, including breast cancers (Calin et al., 2004a; Iorio
et al., 2005; Volinia et al., 2006). One or more members of the
let-7 family regulate RAS expression in human cells, and thus,
let-7 may play a major role in human lung carcinogenesis as a
tumor suppressor gene (Johnson et al., 2005). Recently, miRNA
expression profiles have been shown to be potential tools for
cancer diagnosis (Lu et al., 2005). These and other data are con-
sistent with the hypothesis that miRNAs play a substantial role in
the pathogenesis of human cancers.
In this study, we investigated themiRNA expression profiles in
human lung cancer and miRNA regulation by epigenetic mech-
anisms and found that the miRNA molecular profile of lung ade-
nocarcinoma correlates with patient survival.
Results
Altered miRNA expression in primary lung cancers
and identification of miRNAs associated
with clinicopathological features of lung cancer
We analyzed the miRNA expression in 104 pairs of primary lung
cancers and corresponding noncancerous lung tissues. We
compared miRNA expression of several group pairs as listed in
Table 1. Expression profiles were generated by comparing lung
cancers, except when comparing lung cancer tissues with cor-
responding noncancerous lung tissues. We identified miRNAs,
which were expressed differently in phenotypical and histologi-
cal classifications (Table 1). Whenwe comparedmiRNA expres-
sion among lung cancer tissues versus corresponding noncan-
cerous lung tissues, 43 miRNAs had statistical differences in
expression between groups (Table 2). In class comparison anal-
ysis using our microarray analysis tool, the multivariate permu-
tation test was performed to control multiple comparisons. It190provides a specific confidence level for ensuring that the number
of false discoveries does not exceed a target level or for ensuring
that the proportion of the gene list that are false discoveries does
not exceed a target level. Thus, the probability of identifying at
least 43 miRNAs by chance at the <0.001 level, if there are no
real differences between the classes, was 0 as estimated by
the multivariate permutation test. Furthermore, 91% of 104
lung cancers were correctly classified using the leave-one-out
crossvalidated class predictionmethodbasedon the compound
covariate predictor. Based on 2000 random permutations, the
p value, which is defined as the proportion of the randompermu-
tations that gave a crossvalidated error rate no greater than the
crossvalidated error rate with the real data, was < 0.0005.
Several of thesemiRNAswere associatedwith FRAs (Table 2).
In particular, three miRNAs are located inside FRAs (hsa-mir-21
at FRA17B, hsa-mir-27b at FRA9D, and hsa-mir-32 at FRA9E).
Furthermore, many of these miRNAs are located at frequently
deleted or amplified regions in several malignancies (Table 2).
For example, hsa-mir-21 and hsa-mir-205 are located at the
region amplified in lung cancer, whereas hsa-mir-126* and
hsa-mir-126 are at 9q34.3, a region deleted in lung cancer. Re-
duced expression of precursor let-7a-2 and let-7f-1 was also
found in adenocarcinoma and squamous cell carcinoma at
a p value cutoff of 0.05, respectively. In the same way, compar-
ison analyses between lung adenocarcinoma versus noncan-
cerous tissues and squamous cell carcinoma versus noncan-
cerous tissues revealed 17 and 16 miRNAs with statistically
different expression, respectively (Table S2 in the Supplemental
Data available with this article online). Six miRNAs (hsa-mir-21,
hsa-mir-191, hsa-mir-155, hsa-mir-210, has-mir-126*, and hsa-
mir-224) were shared in both histological types of non-small cell
lung carcinoma (NSCLC).
Next, we asked whether themicroarray data revealed specific
molecular signatures for subsets of lung cancer that differ in clin-
ical behavior. For this analysis, we examined the relationship of
five types of clinical and pathological information (Table 1).
Among them, we identified six miRNAs (hsa-mir-205, hsa-mir-
99b, hsa-mir-203, hsa-mir-202, hsa-mir-102, and hsa-mir-204-
prec) that were expressed differently in the two most common
histological types of NSCLC, adenocarcinoma and squamous
cell carcinoma. The expression levels of hsa-mir-99b and hsa-
mir-102were higher in adenocarcinoma. NomiRNAs were iden-
tified as differently expressed when classified by age, gender, or
race in our data set.
Validation of the microarray data by the solution
hybridization detection method and real-time
RT-PCR analysis
We used the solution hybridization detection method for mature
miRNAs and real-time RT-PCR analysis for precursormiRNAs to
validate the results from microarray analysis. First, the microar-
ray data of three miRNAs (hsa-mir-21, hsa-mir-126*, and hsa-
mir-205) were analyzed by the solution hybridization detection
method. Seven pairs of primary lung cancers and corresponding
noncancerous lung tissues in which sufficient RNA was avail-
able were analyzed. The mature forms of hsa-mir-21 and hsa-
mir-205 were clearly upregulated in lung cancer tissues when
compared with the corresponding noncancerous lung tissues
(Figure 1A). In contrast, hsa-mir-126* was downregulated in
most of the lung cancer tissues examined. Therefore, the anal-
yses confirmed the microarray data for these three miRNAs.CANCER CELL MARCH 2006
A R T I C L ETable 1. Comparison analysis of clinicopathological classifications
Classification (number) Total No. of genes FDR Percent correctly classified (p value)
Phenotypical classification
All tumor (104) versus all normal (104) 208 43 0 91 (<0.0005)
Adeno tumor (65) versus adeno normal (65) 130 17 0.001 80 (<0.0005)
SCC tumor (39) versus SCC normal (39) 78 16 0 92 (<0.0005)
Histological classification
Adeno tumor (65) versus SCC tumor (39) 104 6 0.001 81 (<0.0005)
Age classification
All; age < 67 (56) versus ageR 67 (48) 104 0
Adeno; age < 67 (37) versus ageR 67 (28) 65 0
SCC; age < 67 (19) versus ageR 67 (20) 39 0
Sex classification
All; male (65) versus female (39) 104 0
Adeno; male (39) versus female (26) 65 0
SCC; male (26) versus female (13) 39 0
Race classification
All; African American (21) versus Caucasian (83) 104 0
Adeno; African American (13) versus Caucasian (52) 65 0
SCC; African American (8) versus Caucasian (31) 39 0
Stage classification
All; stage I (65) versus stage II (17) versus stages III and IV (22) 104 0
Adeno; stage I (41) versus stage II (8) versus stages III and IV (16) 65 1
SCC; stage I (24) versus stage II (9) versus stages III and IV (6) 39 0
No. of genes, number of genes significant at 0.001; FDR, false discovery rate, which is probability of significant genes by chance. Percent correctly classified
(p value), the leave-one-out crossvalidated class prediction method based on the compound covariate predictor. The p value is the proportion of the
random permutations that gave a crossvalidated error rate no greater than the crossvalidated error rate with the real data. Adeno, adenocarcinoma;
SCC, squamous cell carcinoma.We also performed real-time RT-PCR analysis of precursor
miRNAs. First, cDNA from 16 pairs of lung adenocarcinoma
and 16 pairs of lung squamous cell carcinoma was prepared
by gene-specific primers (hsa-mir-21, hsa-mir-126*, hsa-mir-
205, and U6), and then, real-time RT-PCR analysis for these
miRNAs and an endogenous control were performed. At least
2-fold upregulation of precursor hsa-mir-21 and hsa-mir-205 ex-
pression was found in 66% and 56% out of 32 cases, respec-
tively, when compared with that in the corresponding noncan-
cerous tissues. The differences were statistically significant at
p < 0.001 by paired Student’s t test (Figure 1B). On the other
hand, 31% of 32 cases examined were found to exhibit >50%
reduction in precursor hsa-mir-126* expression even though
the reduction was not statistically significant (Figure 1B). These
findings show the frequent occurrence of either upregulation or
a reduction of specific precursor miRNAs in lung cancers, as
was seen in the mature miRNAs by using microarray analysis.
Correlation between miRNA expression profiles
and prognosis of lung adenocarcinoma patients
We next investigated the correlation of miRNA expression pro-
files with patient survival. A univariate Cox proportional hazard
regression model with global permutation test in BRB-Array-
Tools indicated that eight miRNAs (hsa-mir-155, hsa-mir-17-
3p, hsa-mir-106a, hsa-mir-93, hsa-let-7a-2, hsa-mir-145, hsa-
let-7b, and hsa-mir-21) were related to the adenocarcinoma
patient’s survival. Patients with high expression of either hsa-
mir-155, hsa-mir-17-3p, hsa-mir-106a, hsa-mir-93, or hsa-mir-
21 and low expression of either hsa-let-7a-2, hsa-let-7b, or
hsa-mir-145were found to have a significantly worse prognosis.CANCER CELL MARCH 2006In addition, the survival analysis among the 41 stage I adenocar-
cinoma patients revealed that three miRNAs (hsa-mir-155, hsa-
mir-17-3p, and hsa-mir-20) were associated with patient out-
come. This indicated the important relationship betweenmiRNA
expression profiles and patient survival, independent of disease
stage.
Because five miRNAs (hsa-mir-155, hsa-mir-17-3p, hsa-let-
7a-2, hsa-mir-145, and hsa-mir-21) out of these miRNAs were
expressed differently among lung cancer tissues versus corre-
sponding noncancerous lung tissues, these miRNAs were
used for further survival analysis. The ratio of lung cancer ex-
pression to corresponding noncancerous lung tissue expres-
sion for each of these five miRNAs was calculated, and the
cases were classified according to the expression ratio. Using
these groupings for eachmiRNA, Kaplan-Meier survival analysis
was performed. Kaplan-Meier survival estimates showed that
the lung adenocarcinoma patients with either high hsa-mir-155
or reduced hsa-let-7a-2 expression had a poorer survival than
the patients with low hsa-mir-155 or high hsa-let-7a-2 expres-
sion, respectively (Figure 2). The difference in the prognosis of
these two groups was statistically significant for hsa-mir-155
(p = 0.006; log-rank test) and marginally significant for hsa-let-
7a-2 (p = 0.033; log-rank test). Survival analysis of the clinico-
pathological factors showed that stage was associated with
survival (p = 0.01; log-rank test), while age, sex, and smoking
history did not account for poor prognosis (Table 3). To adjust
for multiple comparisons, we used the method by Storey and
Tibshirani (2003), limiting the false discovery rates to 0.05.
When this rate was used, hsa-mir-155 and disease stage were
still statistically significant. Subsequently, a multivariate Cox191
A R T I C L ETable 2. Forty-three miRNAs differentially expressed in lung cancer tissues versus noncancerous lung tissues
miRNA Location p value Type FRA associationa Cancer-associated genomic regionsa Host geneb
hsa-mir-21 17q23.2 <1e-07 up FRA17B amp-neuroblastoma; lung cancer TMEM49
hsa-mir-191 3p21.31 <1e-07 up unknown
hsa-mir-126* 9q34.3 <1e-07 down del-NSCLC; HCC EGFL-7
hsa-mir-210 11p15.5 1.00e-07 up del-ovarian; lung cancer unknown
hsa-mir-155 21q21.3 1.00e-07 up amp-colon cancer BIC
hsa-mir-143 5q32 4.00e-07 down del-prostate cancer mlncRNA
hsa-mir-205 1q32.2 4.00e-07 up amp-lung cancer mlncRNA
hsa-mir-192-prec 11q13.1 5.00e-07 down FRA11A del-thyroid cancer mlncRNA
hsa-mir-224 Xq28 5.00e-07 down FRAXF GABRE
hsa-mir-126 9q34.3 7.00e-07 down del-NSCLC; HCC EGFL-7
hsa-mir-24-2 19p13.1 1.30e-06 up ND
hsa-mir-30a-5p 6q13 4.80e-06 down mlncRNA
hsa-mir-212 17p13.3 5.00e-06 up ND
hsa-mir-140 16q22.1 5.10e-06 down ATROPIN-1
hsa-mir-9 15q26.1 6.50e-06 down unknown
hsa-mir-214 1q24.3 8.60e-06 up ND
hsa-mir-17-3p 13q31.3 9.40e-06 up unknown
hsa-mir-124a-1 8p23.1 1.23e-05 down amp-MFHs unknown
hsa-mir-218-2 5q34 1.34e-05 down SLIT3
hsa-mir-95 4p16.1 1.48e-05 down ABLIM2
hsa-mir-145 5q32 1.90e-05 down del-prostate cancer mlncRNA
hsa-mir-198 3q13.33 2.43e-05 down FSTL1
hsa-mir-216-prec 2p16.1 3.05e-05 down ND
hsa-mir-219-1 6p21.32 5.56e-05 down ND
hsa-mir-106a Xq26.2 6.20e-05 up del-ovarian cancer ND
hsa-mir-197 1p13.3 7.23e-05 up ND
hsa-mir-192 11q13.1 0.000119 up FRA11A del-thyroid cancer ND
hsa-mir-125a-prec 19q13.41 0.000143 down mlncRNA
hsa-mir-26a-1-prec 3p22.3 0.000148 down del-epithelial cancer NIF1
hsa-mir-146 5q33.3 0.000163 up mlncRNA
hsa-mir-203 14q32.33 0.000267 up ND
hsa-mir-199b-prec 9q34.11 0.000304 down del-bladder cancer GOLGA2
hsa-let-7a-2-prec 11q24.1 0.000398 down FRA11B del-lung cancer mlncRNA
hsa-mir-27b 9q22.32 0.000454 down FRA9D del-bladder cancer unknown
hsa-mir-32 9q31.3 0.000458 down FRA9E del-lung cancer unknown
hsa-mir-29b-2 1q32.2 0.000466 down mlncRNA
hsa-mir-220 Xq25 0.000630 down ND
hsa-mir-33 22q13.2 0.000683 down del-colon cancer SREBF2
hsa-mir-181c-prec 19p13.12 0.000736 down NANOS3
hsa-mir-150 19q13.33 0.000784 up ND
hsa-mir-101-1 1p31.3 0.000844 down FRA1C del-ovarian; breast cancer ND
hsa-mir-124a-3 20q13.33 0.000968 down ND
hsa-mir-125a 19q13.41 0.000993 down ND
Amp, amplification; del, deletion; NSCLC, non-small cell lung carcinoma; HCC, hepatocellular carcinoma; mlncRNA, mRNA-like noncoding RNA; ND, not
defined; MFHs, malignant fibrous histocytomas.
aInformation was obtained from previous report (Calin et al., 2004b).
bInformation was obtained from previous report (Rodriguez et al., 2004).proportional hazard regression analysis using all of these clini-
copathological and molecular factors indicated that high hsa-
mir-155 expression was a significantly unfavorable prognostic
factor independent of other clinicopathological factors (p =
0.027; risk ratio 3.03; 95% confidence interval [CI], 1.13–8.14)
in addition to disease stage (p = 0.013; risk ratio 3.27; 95% CI,
1.31–8.37) (Table 3).
To investigate the biological consequence of altered hsa-mir-
155 and hsa-let-7a-2 expression, we conducted a bioinformatic
analysis grouping the predicted targets of these miRNAs by
Gene Ontology (GO) terms (Table S2). In addition to associa-
tions with more general functional GO terms, a significant en-
richment for targets associated with transcription was seen for
hsa-mir-155. hsa-let-7a showed an overrepresentation of gene
targets linked with protein kinase and intracellular signaling cas-
cades, a finding consistent with the reported functional interac-
tion between let-7 and RAS (Johnson et al., 2005).192Validation of miRNA expression signature on lung
adenocarcinoma patient survival using an independent
set of adenocarcinoma patients
Real-time RT-PCR analysis was performed for hsa-mir-155
and hsa-let-7a-2 to determine whether the precursor miRNA
expression also had a prognostic impact on adenocarcinoma
patients. First, 32 pairs of adenocarcinomas from the original
set, in which RNA was available, were subjected to real-time
RT-PCR analysis. The ratio of lung cancer expression to corre-
sponding noncancerous lung tissue expression was calculated,
and the cases were classified according to the expression ratio.
Kaplan-Meier survival analysis (Figures S1A and S1B) demon-
strated a significantly worse survival for patients with either
high precursor hsa-mir-155 expression (p = 0.047; log-rank
test) or reduced precursor hsa-let-7a-2 expression (p = 0.037;
log-rank test) (Table 4). To further validate the prognosis classi-
fiers described here, we analyzed an additional independent setCANCER CELL MARCH 2006
A R T I C L EFigure 1. Validation of the microarray data by the solution hybridization detection method and real-time RT-PCR analysis
A: Solution hybridization detection of mature miRNA expression in lung cancers. Ca, cancerous tissues; N, noncancerous lung tissues. rRNA (5S) served as
a loading control.
B: Real-time RT-PCR analysis of precursor miRNA expression in lung cancers. Ca, cancerous tissues; N, noncancerous lung tissues prepared from the same
patient. Paired Student’s t test was performed to ascertain statistical significance between the expression levels in cancer tissue and noncancerous tissues.of 32 adenocarcinomas using real-time RT-PCR analysis. Ka-
plan-Meier survival curves (Figures S1C and S1D) showed
a clear relationship in precursor hsa-mir-155 expression (p =
0.033; log-rank test) and approached significance in hsa-let-
7a-2 expression (p = 0.084; log-rank test) in this cohort as
well (Table 4). In addition, high precursor hsa-mir-155 expres-
sion was found to be an independent predictor of poor progno-
sis by amultivariate Cox proportional hazard regression analysis
(Table 4). To further confirm if there was any grouping bias
between the original set and the additional set, we performed
univariate and multivariate survival analyses for all 64 cases.
Consistently, these analyses showed the significance of precur-
sor hsa-mir-155 expression (Table 4; Figure 3A). Of note,
reduced precursor hsa-let-7a-2 expression also had a similar
prognostic impact on adenocarcinoma patients (Table 4; Fig-
ure 3B) consistent with a previous report (Takamizawa et al.,
2004).CANCER CELL MARCH 2006Lack of epigenetic regulation of miRNA expression
in NSCLC cell lines
We employed miRNA microarray to analyze the changes in
miRNA expression after 5-aza-20-deoxycytidine (5-aza-dC)
and/or Trichostatin A (TSA) treatment in two lung cancer cell
lines, A549 and NCI-H157. Although we could confirm reexpres-
sion of a known transcriptional-silenced gene (MYO18B) as
a positive control (Figure S2), none of themiRNAs showed a sta-
tistically significant change in increased expression after treat-
ment with 5-aza-dC and/or TSA, suggesting that hypermethyla-
tion and histone deacetylation were not responsible for the
reduced miRNA expression in at least these two cells.
Discussion
Little is known about the expression levels or function ofmiRNAs
in normal and neoplastic cells, although it is becoming clear that193
A R T I C L EFigure 2. Kaplan-Meier survival curves for ade-
nocarcinoma patients
Adenocarcinoma cases in which hybridization
intensity was different from background (Experi-
mental Procedures) were classified according
to either hsa-mir-155 expression or hsa-let-7a-2
expression bymiRNAmicroarray analysis. The sur-
vival data were compared using the log-rank
test.
A: hsa-mir-155 high expression (n = 27), group
with the expression ratioRmeanexpression ratio
(1.42). The mean expression ratio is defined as
mean expression ratio = mean of tumor expres-
sion/mean of noncancerous tissue expression.
hsa-mir-155 low expression (n = 28), group with
the expression ratio < mean expression ratio.
B: hsa-let-7a-2 high expression (n = 34), group
with the expression ratioRmeanexpression ratio
(0.95). hsa-let-7a-2 low expression (n = 18), group
with the expression ratio <mean expression ratio.miRNAs play major roles in the regulation of gene expression
during development (Ambros, 2003; McManus, 2003). We re-
ported here that the genome-wide expression profiling of
miRNAs was significantly different among primary lung cancers
and corresponding noncancerous lung tissues. The microarray
data were validated by both solution hybridization detection
method for mature miRNAs and real-time RT-PCR analysis for
precursor miRNAs. Several of the miRNAs identified as differen-
tially expressed are located inside FRAs and/or in the chromo-
somal regions where genomic imbalance in lung cancers has
been observed previously with high frequency. As FRAs are
preferential sites of translocation, deletion, amplification, or inte-
gration of exogenous genome, it is possible that miRNAs lo-
cated near FRAs could be possible targets of such genomic al-
teration. Even though there is the possibility that the differences
in miRNA expression may simply be a surrogate for cytogenetic
changes in lung cancers, the fact that >50% of miRNAs are lo-
cated at cancer-related chromosomal regions supported the
idea that miRNAs may play a role as oncogenes or tumor sup-
pressor genes. Moreover, thesemiRNAs are suggested to be in-
volved in cancer. High expression of mir-155 was found in Bur-
kitt’s lymphoma and B cell lymphomas (Metzler et al., 2004; Eis
et al., 2005). It was also reported that mir-143 and mir-145 are
reduced in colon cancer (Michael et al., 2003). The potential in-
volvement of reduced let-7 expression in lung cancers has been194reported by two different groups (Takamizawa et al., 2004;
Johnson et al., 2005). Consistent with a previous report, we
also found reduced expression of precursor hsa-let-7a-2 and
let-7f-1 in our data set. Overexpression of mir-17-92 cluster
was recently reported in lung cancers, especially in those with
small cell lung cancers (Hayashita et al., 2005).
Precise molecular mechanisms for the altered expression of
miRNAs in lung cancers are unclear. Abnormal expression of
miRNAs in lung cancers could be caused by somatic genetic al-
terations. Alternatively, the reduced expression of miRNAs in
lung cancer could be caused by epigenetic change such as
DNA methylation and alterations of chromatin structure, which
are important processes of transcriptional silencing in many
genes, including tumor suppressor genes, and as an alternative
to genetic defects in human carcinogenesis (Jones and Baylin,
2002; Eberharter and Becker, 2002). The comparison of miRNA
expression between 5-aza-dC- and/or TSA-treated and paren-
tal cell lines is a feasible approach for the identification of differ-
entially expressed cancer-related miRNAs. However, the in-
volvement of the epigenetic regulation for miRNA expression
is unlikely in at least the two NSCLC cell lines we studied. Re-
cently, it was shown that the expression of miRNAsmay be tran-
scriptionally linked to the expression of other genes, coding for
both proteins and noncoding RNAs (Rodriguez et al., 2004; Bas-
kerville and Bartel, 2005). Indeed, approximately 30% of the 43CANCER CELL MARCH 2006
A R T I C L EmiRNAs that showed different expression in lung cancer tissue
versus noncancerous lung tissue are located within exons or in-
trons of known protein-coding genes, such as TMEM49 (trans-
membrane protein 49) for hsa-mir-21, EGFL7 (EGF-like-domain,
multiple 7) for hsa-mir-126* and hsa-mir-126, GABRE (g-amino-
butyric acid [GABA] A receptor, epsilon) for hsa-mir-224 and
SLIT3 (slit homolog 3) for hsa-mir-218-2. TMEM49 is in a
17q23 amplicon that also contains the PPM1D (protein phos-
phatase 1D magnesium-dependent, delta isoform;Wip1) (Bula-
vin et al., 2002), which encodes Ser/Thr protein phosphatase,
inactivates p53 tumor suppressor activity, and facilitates RAS-
and ERBB2-induced murine mammary tumors (Bulavin et al.,
2004). Increased PPM1D expression has not been previously
detected in human lung cancer. EGFL7 is expressed at high
levels in the vasculature of proliferative tissue and is downregu-
lated in mature vessels in the normal adult tissue (Parker et al.,
2004). Future studies will determine the correlation between
Table 3. Postoperative survival of patients with lung adenocarcinoma in
relation to clinicopathological characteristics and miRNA expression
analyzed by microarray analysis
Variable Subset
Hazard ratio (95%
confidence interval) p
Univariate analysis
(n = 65)
Age ageR 67/age < 67 1.41 (0.67–3.06) 0.348
Sex male/female 1.36 (0.64–2.93) 0.413
Stage II–IV/I 2.51 (1.29–6.82) 0.010
Smoking history current/former 1.32 (0.63–2.79) 0.456
hsa-mir-155 (n = 55) high/low 3.42 (1.42–8.19) 0.006
hsa-let-7a-2 (n = 52) low/high 2.35 (1.08–6.86) 0.033
Multivariate analysis
(n = 55)a,b
Age ageR 67/age < 67 1.92 (0.71–5.17) 0.195
Sex male/female 1.23 (0.47–3.22) 0.669
Stage II–IV/I 3.27 (1.31–8.37) 0.013
Smoking history current/former 1.49 (0.51–4.34) 0.457
hsa-mir-155 high/low 3.03 (1.13–8.14) 0.027
aMultivariate analysis, Cox proportional hazard regression model.
bhsa-let-7a-2 low/high was not statistically significant (p = 0.129).CANCER CELL MARCH 2006the expression of these exonic or intronic miRNAs and their
host genes in lung cancers.
The global expression profile of miRNAs with Cox propor-
tional hazard regression analysis could identify miRNAs that
were associated with adenocarcinoma patient survival. The
finding that expression of the five miRNAs (hsa-mir-155, hsa-
mir-17-3p, hsa-let-7a-2, hsa-mir-145, and hsa-mir-21) is statis-
tically altered in lung cancers and also has a prognostic impact
on the survival warrants additional studies to investigate how
altered miRNA expression would manifest the biological conse-
quences in the development and/or progression of human can-
cers. It was recently reported that hsa-mir-21 can function as an
antiapoptotic factor in cultured glioblastoma cells (Chan et al.,
2005). Because hsa-mir-21 expression was upregulated signifi-
cantly in lung cancer tissues, it was speculated that aberrant in-
creased expression of the miRNA might block the expression of
gene products that induce apoptosis and might be related to
lung carcinogenesis. Interestingly, high hsa-mir-155 expression
had a significantly worse prognostic impact on adenocarcinoma
patients as an independent risk factor and therefore could serve
as a marker for survival. A unique 13 miRNA expression sig-
nature including hsa-mir-155 was also a prognostic factor of
chronic lymphocytic leukemia (Calin et al., 2005). Although
mir-155 is overexpressed in several types of human cancer, its
biological function remains still uncertain. However, a previous
study has shown that BIC (host gene of hsa-mir-155) is impli-
cated as a collaborator with c-myc in an avian lymphoma model
system (Tam et al., 2002). We were able to crossvalidate the
clinical importance of outcome predictive miRNAs (hsa-mir-
155 and hsa-let-7a-2) using an independent additional case by
real-time RT-PCR analysis. Again, a multivariate analysis re-
vealed that high precursor hsa-mir-155 expression indepen-
dently contributed to patient outcome. In our study, only hsa-let-
7a-2 of the let-7 family marginally correlated with prognosis in
the original set of adenocarcinomas by miRNA microarray anal-
ysis. The hsa-let-7a-2 expression data remained statistically
sufficient in the original set of adenocarcinomas and was not
statistically significant in the second independent set by real-
time RT-PCR analysis. However, reduced hsa-let-7a-2 expres-
sion correlated with poor survival by univariate analysis as wellTable 4. Postoperative survival of patients with lung adenocarcinoma in relation to clinicopathological characteristics and precursor miRNA expression
analyzed by real-time RT-PCR analysis
Variable Subset
Original cohort (n = 32) Additional cohort (n = 32) All cases (n = 64)
Hazard ratio (95% CI) p Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Univariate analysis
Age ageR 67/age < 67 1.89 (0.62–5.34) 0.274 1.21 (0.46–3.21) 0.679 1.28 (0.64–2.58) 0.482
Sex male/female 0.53 (0.14–1.56) 0.232 1.37 (0.54–3.63) 0.479 0.99 (0.49–1.98) 0.975
Stage II–IV/I 4.22* (1.91–23.6) 0.003 2.37* (1.01–7.83) 0.048 3.07* (1.82–8.84) <0.001
Smoking history current/former 0.92 (0.31–2.66) 0.921 1.22 (0.47–3.16) 0.674 1.12 (0.56–2.25) 0.757
precursor hsa-mir-155 high/low 2.75* (1.05–12.1) 0.047 2.52* (1.10–7.45) 0.033 2.74* (1.53–6.91) 0.002
precursor hsa-let-7a-2 low/high 3.01* (1.09–9.86) 0.037 2.22 (0.91–5.71) 0.084 2.73* (1.42–5.88) 0.003
Multivariate analysis
Age ageR 67/age < 67 0.91 (0.22–3.68) 0.899 0.93 (0.30–2.91) 0.914 1.22 (0.58–2.53) 0.593
Sex male/female 0.35 (0.11–1.17) 0.089 0.92 (0.32–2.66) 0.885 0.85 (0.41–1.74) 0.659
Stage II–IV/I 8.99* (1.95–41.2) 0.004 4.91* (1.51–15.9) 0.008 5.58* (2.42–12.8) <0.001
Smoking history current/former 1.01 (0.30–3.38) 0.980 2.27 (0.70–7.34) 0.170 1.89 (0.85–4.21) 0.117
precursor hsa-mir-155 high/low 13.3* (2.59–69.0) 0.002 3.77* (1.32–10.6) 0.013 4.98* (2.29–10.8) <0.001
precursor hsa-let-7a-2 low/high 3.93* (1.06–14.5) 0.040 2.97* (1.07–8.23) 0.036 3.55* (1.64–7.69) 0.001
CI, confidence interval; multivariate analysis, Cox proportional hazard regression model. Asterisks indicate statistically significant values.195
A R T I C L EFigure 3. Kaplan-Meier survival curves for ade-
nocarcinoma patients
Sixty-four adenocarcinoma cases from two
combined independent cohorts were classified
according to either precursor hsa-mir-155 ex-
pression or precursor hsa-let-7a-2 expression esti-
mated by real-time RT-PCR analysis. The survival
data were compared using the log-rank test.
A: Precursor hsa-mir-155 high expression (n = 27),
group with the expression ratio R mean expres-
sion ratio (1.19). Precursor hsa-mir-155 low ex-
pression (n = 37), groupwith the expression ratio <
mean expression ratio.
B: Precursor hsa-let-7a-2 high expression (n = 33),
group with the expression ratio R mean expres-
sion ratio (0.92). Precursor hsa-let-7a-2 low ex-
pression (n = 31), groupwith the expression ratio <
mean expression ratio.as multivariate analysis in the combined set of two independent
cohorts, suggesting that it is a prognostic factor in lung cancer,
consistent with a previous report (Takamizawa et al., 2004;
Johnson et al., 2005).
Several publications have presented algorithms with which to
identify putative targets for miRNA (Lewis et al., 2003; John
et al., 2004). However, the prediction and validation of target
mRNAs by computerized means and experimental approaches
is a still unresolved task. Recently, it was shown that the let-7
family negatively regulates RAS in C. elegans as well as human
cells, and the downregulation of let-7 could result in the upregu-
lation of RAS and induce oncogenesis in human lung cancer
(Johnson et al., 2005). The GO analysis that we conducted for
putative targets of let-7a was consistent with these findings,
showing an association with target transcripts involved in the in-
tracellular signaling. In addition, our GO analysis for hsa-mir-155
suggests a role for thismiRNA in regulating target transcripts as-
sociated with transcription. Besides this GO analysis, the web-
based computational approaches to predict gene targets were
performed for hsa-mir-155 (miRBase Targets BETA Version
1.0, PicTar predictions, and TargetScan). Table S3 shows ten
putative target genes that were commonly predicted by three
different programs and indicates that the cancer-associated
genes are potentially regulated by this miRNA. However, addi-196tional studies are needed to identify the targets of the miRNAs
and to experimentally correlate them with lung carcinogenesis.
In conclusion, human lung cancer has extensive alterations of
miRNA expression that may deregulate cancer-related genes.
ThemiRNAmolecular profiles of lung adenocarcinoma also cor-
relate with patient survival.
Experimental procedures
Samples
One hundred and four pairs of primary lung cancers and corresponding non-
cancerous lung tissueswere used in this study. An additional 32 cases, which
could be followed up until 5 years, were used for an independent validation
data set. These specimens were obtained from patients in the Baltimoremet-
ropolitan area from 1990 to 1999 with informed consent and IRB agreement.
For the majority of samples, clinical and biological information was available.
Total RNA were isolated by TRIzol (Invitrogen) according to the manufac-
turer’s instructions.
Microarray analysis
Microarray analysis was performed as previously described (Liu et al., 2004).
Briefly, 5 mg of total RNA was used for hybridization on miRNA microarray
chips containing 352 probes in triplicate. The microarrays were hybridized
in 63 SSPE (0.9 M NaCl/60 mM NaH2PO4$2H2O/8 mM EDTA [pH 7.4])/
30% formamide at 25ºC for 18 hr, washed in 0.753 TNT (Tris-HCl/NaCl/
Tween 20) at 37ºC for 40 min, and processed by using a method of directCANCER CELL MARCH 2006
A R T I C L Edetection of the biotin-containing transcripts by streptavidin-Alexa 647 con-
jugate. Processed slides were scanned using a PerkinElmer ScanArray XL5K
Scanner.
An average value of the three spot replicates of each miRNA was normal-
ized and analyzed in BRB-ArrayTools version 3.2.3. After excluding negative
values with hybridization intensity below background, normalizationwas per-
formed by using the median normalization method and normalization to me-
dian array as reference. Finally, we selected 147 miRNAs with consistent log
values present in more than 50% of the samples. We identified genes that
were differently expressed among groups using Student’s t tests or F tests,
and genes were considered statistically significant if their p value was less
than 0.001. We also performed a global test of whether the expression pro-
files differed between the groups by permuting the labels of which arrays cor-
responded to which groups. For each permutation, the p values were recom-
puted, and the number of genes significant at the 0.001 level was noted. The
proportion of the permutations that gave at least as many significant genes
as with the actual data was the significance level of the global test.
For phenotypical and histological comparisons, we performed the class
prediction analysis based on the compound covariate predictor. We esti-
mated the prediction error using leave-one-out crossvalidation. We also
evaluated whether the crossvalidated error rate for a model was significantly
less than one would expect from random prediction. The class labels were
randomly permutated, and the entire leave-one-out crossvalidation process
was repeated 2000 times. All data were submitted to the ArrayExpress data-
base, and the accession number are E-TABE-22.
Solution hybridization detection analysis and real-time RT-PCR
analysis
The expression levels of mature miRNAs were measured by solution hybrid-
ization detection method with mirVana miRNA Detection Kit (Ambion Inc.,
TX). Briefly, total RNA (1 mg) was incubated with radiolabeled probes, which
were prepared by 50 end labeling by T4 Polynucleotide Kinase. Following
digestion to remove the probe that was not bound by target miRNA, the
radiolabeled products were fractionated by denaturing polyacrylamide gel
electrophoresis.
Real-time RT-PCR analysis was performed as described (Schmittgen
et al., 2004). Briefly, RNA was reverse transcribed to cDNA with gene-
specific primers and Thermoscript, and the relative amount of each miRNA
to tRNA for initiator methionine was described, using the equation 22dCT,
where dCT = (CTmiRNA2CTU6). The probe and primer sequences are available
upon request.
5-aza-dC and/or TSA treatment
For the first 48 hr, A549 and NCI-H157 cells (American Tissue Culture Collec-
tion) were incubated with medium containing 1.0 mM 5-aza-dC (Sigma); the
cells were then incubated for another 24 hr with the addition of 1.0 mM TSA
(Sigma). Total RNA was isolated, and then microarray analysis was per-
formed as described above. Each treatment was performed in triplicate.
Survival analysis
We identified genes whose expression was significantly related to survival of
the patient. We computed a statistical significance level for each gene based
on a univariate Cox proportional hazard regression model in BRB-ArrayTools
version 3.2.3. These p values were then used in a multivariate permutation
test in which the survival times and censoring indicators were randomly per-
muted among arrays. Genes were considered statistically significant if their
p value was less than 0.05.
The survival curves were estimated by the Kaplan-Meier method, and the
resulting curveswere compared using the log-rank test. The joint effect of co-
variables was examined using the Cox proportional hazard regression
model. Statistical analysis was performed using StatMate (ATMS Co., Ltd.,
Tokyo, Japan).
GO analysis
Predicted targets of hsa-mir-155 and hsa-let-7a were determined by the
methods of Lewis et al. (2005) and PicTar (Krek et al., 2005) and were ana-
lyzed with respect to the overrepresentation within different biological group-
ing categories including GO. Briefly, the predicted target gene lists were sub-
jected to analysis using WholePathwayScope (WPS) (Yi et al., 2006). The
level of overrepresentation is measured based on Fisher’s exact test onCANCER CELL MARCH 2006a 2 3 2 contingency table for each GO term (whether a gene is in the given
list or not versus whether this gene is associated with a GO term or not).
Then, Fisher’s exact test p values were computed for each term in each GO
and ranked from smaller to higher values to estimate the statistical signifi-
cance andpriority for each term. Those termswith Fisher’s exact test p values
less than 0.005 were listed.
Supplemental data
The Supplemental Data include two supplemental figures and three supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/3/189/DC1/.
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